Scancell - SCIB1 patent granted

Tuesday, Oct 25 2011 by

Scancell, the Nottingham based cancer vaccine developer, announced that a European composition of matter patent has been granted for SCIB1, the company's lead vaccine. SCIB1 is being developed for the treatment of melanoma and is currently in phase I clinical trials.

The SCLP share price has decreased by 41% over the last year.

Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects. Its ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system, where inflammation is stimulated at the tumor site and the cytotoxic T-lymphocyte response, where immune system cells are primed to recognize and kill specific cells. The Moditope immunotherapy platform is based on exploiting the normal immune response to stressed cells, mediated by cluster of differentiation 4+ T cells, and harnessing this mechanism to eradicate cancer cells. more »

LSE Price
18.5p
Change
 
Mkt Cap (£m)
48.4
P/E (fwd)
n/a
Yield (fwd)
n/a



  Is Scancell Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder